| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLURP1 |
| Uniprot No | P55000 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-103aa |
| 氨基酸序列 | LKCYTCKEPMTSASCRTITRCKPEDTACMTTLVTVEAEYPFNQSPVVTRSCSSSCVATDPDSIGAAHLIFCCFRDLCNSEL |
| 预测分子量 | 10.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SLURP1重组蛋白的模拟参考文献示例(基于常见研究主题，非真实文献)：
---
1. **"Recombinant SLURP1 modulates keratinocyte proliferation and differentiation via nicotinic acetylcholine receptors"**
*Arredondo J. et al.*
摘要：研究通过大肠杆菌表达系统制备重组SLURP1蛋白，发现其通过结合α7-nAChR抑制角质形成细胞过度增殖，提示其在银屑病治疗中的潜力。
2. **"Production and functional characterization of human SLURP1 as a potential anti-tumor agent"**
*Adermann K. et al.*
摘要：利用哺乳动物细胞系表达重组SLURP1.证实其通过诱导凋亡抑制多种癌细胞系生长，并揭示其与EGFR信号通路的相互作用。
3. **"Crystal structure of human SLURP1 reveals a conserved Ly6/uPAR fold"**
*Fujii T. et al.*
摘要：解析重组SLURP1的晶体结构，发现其具有典型的三指Ly6结构域，为研究其与胆碱能受体的结合机制提供结构基础。
4. **"SLURP1 recombinant protein alleviates inflammation in murine colitis models"**
*Chimienti F. et al.*
摘要：通过真核表达系统获得功能性SLURP1.证明其通过调节巨噬细胞活性减轻实验性结肠炎模型的炎症反应，支持其作为免疫调节剂的开发价值。
---
注：以上为模拟生成的参考文献，实际研究中请通过PubMed、Google Scholar等平台检索真实文献。
SLURP1 (Secreted Ly-6/UR-paraoxonase domain-containing protein 1) is a small, secreted glycoprotein belonging to the Ly-6/uPAR protein family, characterized by a conserved Ly-6/uPAR domain. This structural motif, common in cell surface and secreted proteins, forms a three-finger fold critical for receptor interactions. SLURP1 is primarily expressed in epithelial and immune cells, playing roles in epidermal homeostasis, inflammation regulation, and cell signaling.
Functionally, SLURP1 modulates nicotinic acetylcholine receptors (nAChRs), particularly the α7 subtype, influencing keratinocyte differentiation, apoptosis, and immune responses. Dysregulation of SLURP1 is linked to pathological conditions. For instance, mutations in the *SLURP1* gene cause Mal de Meleda, a rare autosomal recessive palmoplantar keratoderma characterized by thickened skin on palms and soles. Altered SLURP1 expression is also associated with psoriasis, cancer progression, and chronic inflammation, highlighting its therapeutic relevance.
Recombinant SLURP1 is produced using expression systems like *E. coli* or mammalian cells, enabling studies of its molecular mechanisms and therapeutic potential. Purified recombinant SLURP1 retains bioactivity, facilitating research into its anti-inflammatory, anti-proliferative, and immunomodulatory effects. In preclinical models, it has shown promise in mitigating skin disorders and cancer by regulating nAChR-mediated pathways and cytokine release. Additionally, recombinant SLURP1 serves as a tool to explore its interactions with extracellular matrix components and signaling receptors, offering insights into tissue-specific targeting strategies. Its dual role as a signaling molecule and disease biomarker underscores its importance in both basic research and translational applications.
×
